Assembly Biosciences, Inc.: other noncurrent assets

What this measure means

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Exact concept: us-gaap:OtherAssetsNoncurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Assembly Biosciences, Inc.: total assets
• Assembly Biosciences, Inc.: total liabilities
• Assembly Biosciences, Inc.: stockholders equity
• Assembly Biosciences, Inc.: cash and cash equivalents
• Assembly Biosciences, Inc.: net income or loss
• Assembly Biosciences, Inc.: operating cash flow
• Assembly Biosciences, Inc.: capital expenditure payments
• Assembly Biosciences, Inc.: financing cash flow
• Assembly Biosciences, Inc.: investing cash flow
• Assembly Biosciences, Inc.: retained earnings or deficit
• Assembly Biosciences, Inc.: basic weighted-average shares
• Assembly Biosciences, Inc.: diluted weighted-average shares
• Assembly Biosciences, Inc.: basic earnings per share
• Assembly Biosciences, Inc.: diluted earnings per share
• Assembly Biosciences, Inc.: income tax expense or benefit
• Assembly Biosciences, Inc.: net property, plant and equipment
• Assembly Biosciences, Inc.: share-based compensation expense
• Assembly Biosciences, Inc.: operating income or loss
• Assembly Biosciences, Inc.: current assets
• Assembly Biosciences, Inc.: interest expense
• Assembly Biosciences, Inc.: current liabilities
• Assembly Biosciences, Inc.: current accounts payable
• Assembly Biosciences, Inc.: goodwill carrying amount
• Assembly Biosciences, Inc.: net current accounts receivable
• Assembly Biosciences, Inc.: operating expenses
• Assembly Biosciences, Inc.: research and development expense
• Assembly Biosciences, Inc.: common shares outstanding
• Assembly Biosciences, Inc.: additional paid-in capital
• Assembly Biosciences, Inc.: accumulated other comprehensive income or loss
• Assembly Biosciences, Inc.: operating lease right-of-use asset
• Assembly Biosciences, Inc.: operating lease liability
• Assembly Biosciences, Inc.: gross property, plant and equipment
• Assembly Biosciences, Inc.: accumulated depreciation on property, plant and equipment
• Assembly Biosciences, Inc.: net intangible assets excluding goodwill
• Assembly Biosciences, Inc.: accrued current liabilities
• Assembly Biosciences, Inc.: prepaid expenses and other current assets
• Assembly Biosciences, Inc.: current contract liabilities
• Assembly Biosciences, Inc.: net deferred tax assets
• Assembly Biosciences, Inc.: net deferred tax liabilities
• Assembly Biosciences, Inc.: pre-tax income or loss from continuing operations
• Assembly Biosciences, Inc.: profit or loss including noncontrolling interests
• Assembly Biosciences, Inc.: comprehensive income or loss
• Assembly Biosciences, Inc.: general and administrative expense
• Assembly Biosciences, Inc.: depreciation expense
• Assembly Biosciences, Inc.: depreciation, depletion and amortization
• Assembly Biosciences, Inc.: nonoperating income or expense
• Assembly Biosciences, Inc.: current income tax expense or benefit
• Assembly Biosciences, Inc.: deferred income tax expense or benefit
• Assembly Biosciences, Inc.: proceeds from issuing common stock
• Assembly Biosciences, Inc.: operating lease payments
• Assembly Biosciences, Inc.: change in accounts receivable
• Assembly Biosciences, Inc.: change in accounts payable

Inspect the source

Entity

Assembly Biosciences, Inc. / CIK 0001426800

Captured

2026-09-20T08:03:55.156Z

SEC response SHA-256

f87ee3d44f43bd73d30c280e8d97b2de4bcc4d8a35b03fbebb0e715c83069335

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001426800.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))